- Farhad Hafezi, Scientific article
- por Mark Hillen
- Julho 3, 2022
Members of the ELZA Institute were instrumental in the introduction of cross-linking technology (CXL) in ophthalmology. ELZA’s Medical Director, Farhad Hafezi, has published more than 110 scientific publications on CXL (as of July 2021) and is internationally recognized as a pioneer of this method. In 2014, he received the prestigious Carl Camras Award for Translational Research from the Association for Research in Vision and Ophthalmology (ARVO) for his translational research in the field, and in 2019 was appointed a Fellow of ARVO (FARVO) – a great honour.
Prof. Hafezi co-founded the International Cross-Linking Congress and has co-organized it since its inception in 2006. He has been co-Editor of the main textbook on Corneal Cross-Linking from SLACK, Inc. since 2012, and has been voted among the 100 most influential people in Ophthalmology in the world, for his services to refractive surgery and cross-linking technology.
Reticulação (CXL)
Crosslinking
In addition to scientific expertise, patients from around the world are treated at the ELZA Institute using the latest scientifically proven CXL techniques.
Members of the ELZA Institute were the first to use CXL in the postoperative treatment of ectasia after LASIK / PRK, in very thin corneas and for corneal infections. In addition, we have developed a nomogram, which allows a keratoconus to be lasered with great precision in such a way as to improve image quality, and the nomogram we have developed for ablating previously cross-linked corneal tissue has been used worldwide since spring 2017 in modern excimer laser systems.
